HD-OPM Archive
Hashtags

#dayspring

16 posts

Boston Heart's desmosterol test is likely a waste of money, argues Louis

Jan 15, 2024 · Louis Nervegna ♥ 13 · 💬 15 Risk assessment & lab tests

Louis critiques the desmosterol blood test, a marker of cholesterol production marketed for predicting statin response and Alzheimer's risk. He argues statin response can simply be checked by trying a statin, and that in healthy people high (not low) desmosterol is associated with higher dementia risk, so claims that statins raise Alzheimer's risk via lowering desmosterol are backwards. Even the test maker's material says lower desmosterol is optimal.

Statin dose-response: the lowest dose gives the biggest percentage LDL drop per mg

Oct 23, 2026 · Louis Nervegna ♥ 19 · 💬 7 Statins

Louis shares a Tom Dayspring slide showing diminishing returns with statin dose: 10 mg atorvastatin lowers LDL about 37%, with 20 mg adding 6%, 40 mg adding 5% and 80 mg adding 3%. His advice is to lower LDL with lifestyle first, then use the lowest effective statin dose, taking a low dose being better than quitting.

Circulating oxidized LDL is a poor test; measure ApoB instead, says Dayspring

Feb 04, 2024 · Louis Nervegna ♥ 9 · 💬 12 LDL, ApoB & lipid panel

Tom Dayspring argues that oxidized LDL measured in the bloodstream is a 'useless' biomarker and that ApoB should be measured instead. Louis adds that this refers to circulating oxidized LDL, not oxidized LDL inside plaques, which still matters but cannot be measured by blood test. Newer studies that adjust for ApoB reportedly show circulating oxidized LDL is not related to CVD risk.